# BUY CEAT

# Delivering on growth; margins to follow

Auto & Auto Ancillaries > Result Update > January 17, 2025

CEAT recorded accelerated revenue growth of 11% in Q3FY25 (~7.9%/1.5% volume /realization growth) with EBITDA ~5% above Consensus', despite the ~60bps QoQ margin decline to 10.3% amid the ~1% higher RM. CEAT has guided to growth momentum continuing, with Truck/Bus, 2W, and Farm/PV replacement seen growing in a high single digit, double digits, and a low single digit, respectively, and further market share gains in consumer OEM categories along with sustained double digit growth in exports. While RM inflation remained ahead of price hikes in Q3FY25, RM is seen as largely stable (+/- 1%) in Q4FY25, with further price hikes on the anvil – including in 2Ws. CEAT expects to return to the higher-end of the 10-15% EBITDA margin band over FY26, if RM prices sustain at current levels. While margin recovery appears slightly delayed, we expect CEAT's consumer-facing product mix and continuing market-leading growth to cushion the impact. We cut FY25E/26E/27E EPS by ~8%/~4%/~2%, respectively, with bulk of the cut being attributable to higher than expected interest costs. We maintain BUY on CEAT, with unchanged TP of Rs4,000 at 18x Dec-26E PER.

#### **CEAT:** Financial Snapshot (Consolidated)

CLAT. Thancial Shapshot (Consolidated)										
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E					
Revenue	113,149	119,435	131,629	146,064	160,686					
EBITDA	9,738	16,523	14,387	18,010	20,809					
Adj. PAT	2,196	7,009	5,075	7,367	9,247					
Adj. EPS (Rs)	54.3	173.3	125.5	182.1	228.6					
EBITDA margin (%)	8.6	13.8	10.9	12.3	13.0					
EBITDA growth (%)	39.7	69.7	(12.9)	25.2	15.5					
Adj. EPS growth (%)	117.0	245.2	(21.0)	45.1	25.5					
RoE (%)	6.5	18.7	12.0	15.6	17.0					
RoIC (%)	7.5	16.1	12.2	15.4	17.1					
P/E (x)	56.1	17.6	24.3	16.7	13.3					
EV/EBITDA (x)	14.9	8.5	9.8	7.7	6.5					
P/B (x)	3.6	3.0	2.8	2.4	2.1					
FCFF yield (%)	2.3	6.1	2.6	4.3	4.8					

Source: Company, Emkay Research

#### Double-digit revenue growth; QoQ margin decline curtailed via strategic price hikes

Consol revenue grew 11% YoY to Rs33bn (above estimates) aided by 7.9%/1.5% volume/realization growth. EBITDA was down 6% QoQ to Rs3.4bn, but above consensus estimates. EBITDA margin declined by 63bps QoQ to 10.3%, with gross margin contraction restricted to ~59bps QoQ via active pricing actions partially offsetting the ~1.2% QoQ rise in natural rubber prices during the quarter. Adj PAT at ~Rs971mn was 5% below consensus', amid higher than expected interest (due to higher average debt during the quarter) and tax expense.

### Earnings call KTAs

1) The management has guided to continued growth momentum O4, with the Truck/Bus replacement segment expected to grow in a high single digit, 2W replacement potentially in double digits, Farm/PVs replacement in a low single digits, and margin-accretive exports in double digits. 2) Growth is anticipated to relatively accelerate in the consumer OEM segments (2Ws/4Ws), amid market share gains through increased fitments; TBR segment to consolidate, despite a low single digit decline in MHCV volumes. On the rural front, the farm/2W replacement segment is seeing robust growth owing to favorable macros. 3) CEAT is inching toward double digit market share in a consolidated OHT market; PV segment market share has been largely stable over the quarters. 4) The US market is expected to contribute 20-30% of exports in the next 2-3 years, while the EU is nearing 10% of total turnover (in a single digit now). While LatAm faces headwinds, the US is seeing growth in OTR and TBR, with PCR introduction from FY26. The EU market is performing well in OHT. 5) CEAT aims to retain Camso's premium positioning and pricing, targeting customers in international (EU and US) markets; OHT segment revenue contribution would nearly double (~15% now), with share of exports growing to ~26% (vs 19% now) post consolidation of Camso in Q1FY26. 6) In Q3, CEAT took price hikes across categories in the replacement segment - 1.5% in Farm/CVs and 4% in PVs; further hikes are planned in the export and replacement segments in Q4; owing to robust growth and higher competition in 2Ws, price hikes were restricted to ~1% (at the end of Q3; would continue in Q4FY25); further 5-6 price hikes would be needed to close the pricing gap in 2Ws; price hikes to be enforced in 3Ws by end of Jan-25. CEAT has secured 3-4% price benefit in indexed OEMs and negotiated additional increases with CV OEMs. 7) Business mix improvement and price increases were insufficient to offset the 1.2% QoQ RM inflation in Q3, and RM costs are expected to be flattish (+/-1%) QoQ, contingent on crude prices and currency depreciation; The management expects to reach the higher end of the 10-15% EBITDA margin band over FY26, given that RM prices remain stable at current levels as it would take ~6-9 months to pass-on any price increase. 8) The proposed 30% capacity expansion of 2W/3W tyre capacity to 35mn tyres pa (vs 27mn now) would entail a capex of ~Rs4bn, with completion targeted for FY28. This would be funded by a mix of internal accruals and debt. PCR/TBR capacity at the Chennai plant is also under discussions. However, the management has maintained its guidance of bite-size capex of ~Rs10.5bn for FY25. 9) Overall utilization levels remain above 85%, with the Halol plant functioning at 95% utilization. 10) Working capital / debt has reduced by Rs840mn/500mn in Q3; net debt/EBITDA stands at 1.22x, and net debt/equity at 0.43x.




#### TARGET PRICE (Rs): 4,000

Target Price – 12M	Dec-25
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	31.4
CMP (16-Jan-25) (Rs)	3,044.0
Stock Data	Ticker
52-week High (Rs)	3,581
52-week Low (Rs)	2,210
Shares outstanding (mn)	40.5
Market-cap (Rs bn)	123
Market-cap (USD mn)	1,423
Net-debt, FY25E (Rs mn)	17,453
ADTV-3M (mn shares)	-
ADTV-3M (Rs mn)	874.1
ADTV-3M (USD mn)	10.1
Free float (%)	52.8
Nifty-50	23,312
INR/USD	86.6
Shareholding, Sep-24	

FPIS/MFS (%	<b>(</b> 0 )	10	6.7/19.7					
Price Performance								
(%)	1M	3M	12M					
<b>`</b> . <b>`</b> .								

47.2





Promoters (%)



#### Chirag Jain

chirag.jain@emkayglobal.com +91 22 6624 2428

#### Jaimin Desai

jaimin.desai@emkayglobal.com +91 22 6612 1334

#### Nandan Pradhan

nandan.pradhan@emkayglobal.com +91 22 6612 1238

#### Omkar Rane

omkar.rane@emkayglobal.com +91 22 6624 2414

#### Marazbaan Dastur

marazbaan.dastur@emkayglobal.com +91 22 6612 1281

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>Please refer to the last page of the report on Restrictions Refer to Important Disclosures at the end of this report on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

(Rs mn)	Q1 FY24	Q2 FY24	Q3FY24	Q4 FY24	Q1 FY25	Q2 FY25	Q3 FY25	YoY (%)	QoQ (%)
Revenue	29,352	30,533	29,631	29,919	31,928	33,045	32,999	11.4	(0.1)
Expenditure	25,481	25,972	25,456	26,003	28,099	29,423	29,590	16.2	0.6
as % of sales	86.8	85.1	85.9	86.9	88.0	89.0	89.7		
Consumption of RM	17,296	17,298	17,385	17,265	19,401	20,683	20,847	19.9	0.8
as % of sales	58.9	56.7	58.7	57.7	60.8	62.6	63.2		
Employee Cost	1,955	2,177	2,172	2,153	1,956	2,190	2,159	(0.6)	(1.4)
as % of sales	6.7	7.1	7.3	7.2	6.1	6.6	6.5		
Other expenditure	6,230	6,498	5,899	6,585	6,742	6,550	6,584	11.6	0.5
as % of sales	21.2	21.3	19.9	22.0	21.1	19.8	20.0		
EBITDA	3,871	4,561	4,175	3,915	3,829	3,623	3,409	(18.3)	(5.9)
EBITDA margin (%)	13.2	14.9	14.1	13.1	12.0	11.0	10.3		
Depreciation	1,209	1,245	1,273	1,361	1,318	1,371	1,415	11.1	3.2
EBIT	2,662	3,316	2,902	2,555	2,511	2,252	1,994	(31.3)	(11.4)
Other Income	33	105	29	31	62	35	34	16.7	(0.6)
Interest	701	717	656	617	619	665	751	14.6	13.0
PBT	1,993	2,704	2,276	1,969	1,954	1,622	1,278	(43.9)	(21.2)
Total Tax	529	683	544	458	540	463	361	(33.6)	(22.0)
Adjusted PAT	1,464	2,021	1,731	1,510	1,414	1,159	916	(47.1)	(20.9)
MI and Inc from JV	(18)	59	84	157	53	61	55	(34.3)	(9.1)
Adjusted PAT after MI	1,446	2,080	1,815	1,667	1,467	1,219	971	(46.5)	(20.3)
Exceptional Loss/(Gain)	-	-	-	(582)	75	(3)	-		
Reported PAT	1,446	2,080	1,815	1,086	1,542	1,216	971	(46.5)	(20.1)
Adjusted EPS (Rs)	35.8	51.4	44.9	26.8	38.1	30.1	24.0	(46.5)	(20.1)

(%)	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	YoY (bps) (	QoQ (bps)
Gross Margin	41.1	43.3	41.3	42.3	39.2	37.4	36.8	(450)	(59)
EBITDAM	13.2	14.9	14.1	13.1	12.0	11.0	10.3	(376)	(63)
EBITM	9.1	10.9	9.8	8.5	7.9	6.8	6.0	(375)	(77)
EBTM	6.8	8.9	7.7	6.6	6.1	4.9	3.9	(381)	(104)
PATM	4.9	6.8	6.1	5.6	4.6	3.7	2.9	(318)	(75)
Effective Tax rate	26.5	25.3	23.9	23.3	27.6	28.6	28.3	437	(27)

Source: Company, Emkay Research

# Exhibit 2: Actual vs Estimates: Margin beat vs consensus

(Rs mn)	Actual	Emkay Est	Variance	Consensus	% Variance
Net sales	32,999	32,002	3.1	33,467	(1.4)
EBITDA	3,409	3,456	(1.4)	3,254	4.8
EBITDA margin (%)	10.3	10.8	-47 bps	9.7	61 bps
Adj net income	971	1,185	(18.1)	1,023	(5.1)
FDEPS (Rs)	24.0	29.3	(18.1)	NA	

Source: Company, Emkay Research








Exhibit 4: ...with international rubber prices also down, by 16% from the recent highs



Source: Bloomberg, Emkay Research

Source: Bloomberg, Emkay Research

### Exhibit 5: Crude prices have recently risen due to the unfavorable geo-political situation



Source: Bloomberg, Emkay Research

#### Exhibit 6: Revenue Model - We build in 10%/20%/35% revenue/EBITDA/EPS CAGR over FY25-27E

Exhibit 6: Revenue Model – we i		0 /0/ 33 /0 leve	ende/EbirbA	P S CAGR OV	er 1125-27E			
Segment (Rs mn)	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Truck and Bus	20,336	25,873	28,090	33,945	37,025	39,987	43,186	46,641
% of Revenues	30.0	34.0	30.0	30.0	31.0	30.4	29.6	29.0
Growth YoY (%)	-9.0	27.2	8.6	20.8	9.1	8.0	8.0	8.0
2/3Ws	21,692	22,068	27,154	29,419	32,247	36,762	42,093	47,144
% of Revenues	32.0	29.0	29.0	26.0	27.0	27.9	28.8	29.3
Growth YoY (%)	0.2	1.7	23.0	8.3	9.6	14.0	14.5	12.0
PC/UV	9,490	10,653	16,854	22,630	23,887	25,858	28,314	31,004
% of Revenues	14.0	14.0	18.0	20.0	20.0	19.6	19.4	19.3
Growth YoY (%)	-2.9	12.3	58.2	34.3	5.6	8.3	9.5	9.5
OHT/Speciality	8,135	10,653	13,109	18,104	17,915	20,244	23,078	25,848
% of Revenues	12.0	14.0	14.0	16.0	15.0	15.4	15.8	16.1
Growth YoY (%)	5.9	31.0	23.0	38.1	-1.0	13.0	14.0	12.0
LCV/others	8,135	6,849	8,427	9,052	8,360	8,778	9,393	10,050
% of Revenues	12.0	9.0	9.0	8.0	7.0	6.7	6.4	6.3
Growth YoY (%)	-2.9	-15.8	23.0	7.4	-7.6	5.0	7.0	7.0
Total Consolidated Revenues	67,788	76,096	93,634	113,149	119,435	131,629	146,064	160,686
Growth YoY (%)	-2.9	12.3	23.0	20.8	5.6	10.2	11.0	10.0
EBITDA	6,970	9,522	6,969	9,738	16,523	14,387	18,010	20,809
EBITDA margin (%)	10.3	12.5	7.4	8.6	13.8	10.9	12.3	13.0
EBIT	4,205	6,125	2,617	5,045	11,434	8,864	11,686	13,811
EBIT margin (%)	6.2	8.0	2.8	4.5	9.6	6.7	8.0	8.6
Interest	1,539	1,788	2,070	2,421	2,691	2,594	2,416	2,078
PBT	3,043	4,839	949	2,793	8,941	6,469	9,472	11,937
Tax rate (%)	24	11	26	26	25	25	25	25
РАТ	2,312	4,320	712	2,196	7,009	5,075	7,367	9,247
PAT margin (%)	3.4	5.7	0.8	1.9	5.9	3.9	5.0	5.8
EPS (Rs)	57.2	106.8	17.6	54.3	173.3	125.5	182.1	228.6


Source: Company, Emkay Research; Our estimates currently do not include the effect of consolidation of Camso.

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY-GOS. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research ed at 02 analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 7: We cut FY25E/26E/27E EPS by 8%/4%/2.4%, largely led by slight delay in margin recovery and higher than expected interest cost

(Da ma)		FY25E			FY26E				FY27E			
(Rs mn)	Earlier	Revised	% Change	% YoY	Earlier	Revised	% Change	% YoY	Earlier	Revised	% Change	% YoY
Revenue	130,112	131,629	1.2	10.2	144,604	146,064	1.0	11.0	157,886	160,686	1.8	10.0
EBITDA	14,833	14,387	(3.0)	(12.9)	18,220	18,010	(1.2)	25.2	20,841	20,809	(0.2)	15.5
Margin (%)	11.4	10.9	(47)bps	(47)bps	12.6	12.3	(27)bps	140bps	13.2	13.0	(25)bps	62bps
APAT	5,519	5,075	(8.0)	(27.6)	7,676	7,367	(4.0)	45.1	9,475	9,247	(2.4)	25.5
EPS (Rs)	136	125	(8.0)	(27.6)	190	182	(4.0)	45.1	234	229	(2.4)	25.5

Source: Company, Emkay Research



Source: Company, Emkay Research

# **CEAT: Consolidated Financials and Valuations**

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	113,149	119,435	131,629	146,064	160,686
Revenue growth (%)	20.8	5.6	10.2	11.0	10.0
EBITDA	9,738	16,523	14,387	18,010	20,809
EBITDA growth (%)	39.7	69.7	(12.9)	25.2	15.5
Depreciation & Amortization	4,693	5,088	5,523	6,323	6,998
EBIT	5,045	11,434	8,864	11,686	13,811
EBIT growth (%)	92.8	126.6	(22.5)	31.8	18.2
Other operating income	0	0	0	0	0
Other income	169	197	199	201	203
Financial expense	2,421	2,691	2,594	2,416	2,078
РВТ	2,793	8,941	6,469	9,472	11,937
Extraordinary items	334	582	0	0	0
Taxes	718	2,214	1,630	2,368	2,984
Minority interest	(38)	(74)	(7)	(7)	(7)
Income from JV/Associates	82	208	229	256	287
Reported PAT	1,862	6,427	5,075	7,367	9,247
PAT growth (%)	117.0	245.2	(21.0)	45.1	25.5
Adjusted PAT	2,196	7,009	5,075	7,367	9,247
Diluted EPS (Rs)	54.3	173.3	125.5	182.1	228.6
Diluted EPS growth (%)	117.0	245.2	(21.0)	45.1	25.5
DPS (Rs)	12.0	30.0	30.0	30.0	30.0
Dividend payout (%)	26.1	18.9	23.9	16.5	13.1
EBITDA margin (%)	8.6	13.8	10.9	12.3	13.0
EBIT margin (%)	4.5	9.6	6.7	8.0	8.6
Effective tax rate (%)	25.7	24.8	25.2	25.0	25.0
NOPLAT (pre-IndAS)	3,749	8,603	6,630	8,765	10,358
Shares outstanding (mn)	40.5	40.5	40.5	40.5	40.5

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	405	405	405	405	405
Reserves & Surplus	33,992	40,022	43,883	50,037	58,070
Net worth	34,396	40,426	44,288	50,441	58,475
Minority interests	174	97	90	83	76
Deferred tax liability (net)	3,873	4,509	4,509	4,509	4,509
Total debt	22,955	17,915	19,139	19,515	16,617
Total liabilities & equity	61,398	62,948	68,026	74,549	79,677
Net tangible fixed assets	30,880	59,268	61,775	66,008	70,124
Net intangible assets	878	973	973	973	973
Net ROU assets	29,203	2,470	2,470	2,470	2,470
Capital WIP	5,961	6,835	9,306	9,749	10,635
Goodwill	0	0	0	0	C
Investments [JV/Associates]	1,696	1,821	1,821	1,821	1,821
Cash & equivalents	719	591	1,686	4,316	4,641
Current assets (ex-cash)	26,929	27,987	30,845	34,541	38,879
Current Liab. & Prov.	34,868	36,997	40,849	45,328	49,866
NWC (ex-cash)	(7,938)	(9,010)	(10,004)	(10,787)	(10,987)
Total assets	61,398	62,948	68,026	74,549	79,677
Net debt	22,236	17,324	17,453	15,200	11,976
Capital employed	61,398	62,948	68,026	74,549	79,677
Invested capital	53,023	53,701	55,213	58,664	62,581
BVPS (Rs)	850.3	999.4	1,094.9	1,247.0	1,445.6
Net Debt/Equity (x)	0.6	0.4	0.4	0.3	0.2
Net Debt/EBITDA (x)	2.3	1.0	1.2	0.8	0.6
Interest coverage (x)	0.5	0.2	0.3	0.2	0.1
RoCE (%)	8.4	18.4	13.5	16.4	18.2

Source: Company, Emkay Research

Valuations and key R	atios				
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	56.1	17.6	24.3	16.7	13.3
P/CE(x)	17.9	10.2	11.6	9.0	7.6
P/B (x)	3.6	3.0	2.8	2.4	2.1
EV/Sales (x)	1.3	1.2	1.1	0.9	0.8
EV/EBITDA (x)	14.9	8.5	9.8	7.7	6.5
EV/EBIT(x)	28.8	12.3	15.9	11.8	9.8
EV/IC (x)	2.7	2.6	2.5	2.4	2.2
FCFF yield (%)	2.3	6.1	2.6	4.3	4.8
FCFE yield (%)	0.9	4.9	1.0	3.0	3.7
Dividend yield (%)	0.4	1.0	1.0	1.0	1.0
DuPont-RoE split					
Net profit margin (%)	1.9	5.9	3.9	5.0	5.8
Total asset turnover (x)	1.9	1.9	2.0	2.0	2.1
Assets/Equity (x)	1.8	1.7	1.5	1.5	1.4
RoE (%)	6.5	18.7	12.0	15.6	17.0
DuPont-RoIC					
NOPLAT margin (%)	3.3	7.2	5.0	6.0	6.4
IC turnover (x)	2.1	2.2	2.4	2.5	2.6
RoIC (%)	7.5	16.1	12.2	15.4	17.1
Operating metrics					
Core NWC days	(25.6)	(27.5)	(27.7)	(27.0)	(25.0)
Total NWC days	(25.6)	(27.5)	(27.7)	(27.0)	(25.0)
Fixed asset turnover	1.5	1.5	1.5	1.5	1.5
Opex-to-revenue (%)	26.1	28.2	26.6	26.4	26.7

Source: Company, Emkay Research

Y/E Mar (Rs mn)

FY23

FY24

FY25E

FY26E

FY27E

Source: Company, Emkay Research

**Cash flows** 

PBT 2,793 8,941 6,469 9,472 11,937 7,008 7,789 Others (non-cash items) 8.117 8,739 9,075 377 (1,630) (1,630) (2,368) (2,984) Taxes paid Change in NWC 2,211 2,674 994 783 199 Operating cash flow 12,055 17,193 14,179 16.883 18.514 Capital expenditure (8,779) (8,668) (10,500) (11,000) (12,000) Acquisition of business (11) (44) 0 0 0 Interest & dividend income 299 175 175 175 175 Investing cash flow (10,500) (8,491) (8,537) (11,000) (12.000)Equity raised/(repaid) 0 0 0 0 0 Debt raised/(repaid) (977) (5,556) 1,224 376 (2.898) Payment of lease liabilities 936 918 918 918 918 Interest paid (2,093) (2,669) (2,594) (2,416) (2,078) Dividend paid (incl tax) (126) (485) (1,214) (1,214) (1,214) Others 0 0 0 0 0 (3,195) Financing cash flow (8,710) (2,583) (3,253) (6,189) Net chg in Cash 369 (54) 1,095 2,630 325 OCF 12.055 17.193 14,179 16,883 18.514 Adj. OCF (w/o NWC chg.) 9,844 14,518 13,185 16,099 18,315 FCFF 3,276 8,525 3,679 5,883 6,514 FCFE 1,154 6,009 1,260 3,641 4,611 OCF/EBITDA (%) 123.8 104.1 98.6 93.7 89.0 FCFE/PAT (%) 62.0 93.5 24.8 49.4 49.9 FCFF/NOPLAT (%) 87.4 99.1 55.5 67.1 62.9

Source: Company, Emkay Research

# **RECOMMENDATION HISTORY - DETAILS**

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
10-Jan-25	3,084	4,000	Buy	Chirag Jain
11-Dec-24	3,149	4,000	Buy	Chirag Jain
08-Dec-24	3,096	3,650	Buy	Chirag Jain
21-Oct-24	2,972	3,650	Buy	Chirag Jain
03-Sep-24	2,849	3,650	Buy	Chirag Jain

Source: Company, Emkay Research

# **RECOMMENDATION HISTORY - TREND**



Source: Company, Bloomberg, Emkay Research

# GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Marke

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

#### **RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

#### ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons1 may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function is handled appropriately.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of January 17, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of January 17, 2025
- 5. EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the January 17, 2025
- 6. EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- 7. EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for
- investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 8. EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

#### Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	<15% downside

#### Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

#### OTHER DISCLAIMERS AND DISCLOSURES:

# Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject Company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates for the subject company in the past twelve months.